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Abstract. Purpose: Acute renal tubular necrosis (ATN), a
common cause of acute renal failure, is a dynamic, rapidly
evolving clinical condition associated with apoptotic and
necrotic tubular cell death. Its early identification is crit-
ical, but current detection methods relying upon clinical
assessment, such as kidney biopsy and functional assays,
are insufficient. We have developed a family of small
molecule compounds, ApoSense, that is capable, upon
systemic administration, of selectively targeting and accu-
mulating within apoptotic/necrotic cells and is suitable for
attachment of different markers for clinical imaging. The
purpose of this study was to test the applicability of these
molecules as a diagnostic imaging agent for the detection
of renal tubular cell injury following renal ischemia.
Methods: Using both fluorescent and radiolabeled deriva-
tives of one of the ApoSense compounds, didansyl cystine,
we evaluated cell death in three experimental, clinically
relevant animal models of ATN: renal ischemia/reperfu-
sion, radiocontrast-induced distal tubular necrosis, and
cecal ligature and perforation-induced sepsis.
Results: ApoSense showed high sensitivity and specificity
in targeting injured renal tubular epithelial cells in vivo in
all three models used. Uptake of ApoSense in the ischemic
kidney was higher than in the non-ischemic one, and the
specificity of ApoSense targeting was demonstrated by its
localization to regions of apoptotic/necrotic cell death,
detected morphologically and by TUNEL staining.
Conclusion: ApoSense technology should have significant
clinical utility for real-time, noninvasive detection of renal
parenchymal damage of various types and evaluation of its
distribution and magnitude; it may facilitate the assess-
ment of efficacy of therapeutic interventions in a broad
spectrum of disease states.
Keywords: Apoptosis imaging – Cell death detection –
Renal disease – Renal uptake – Small animal imaging
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Introduction
Acute renal failure (ARF) that results from ischemic or
toxic insults to the kidney is usually referred to clinically as
acute tubular necrosis (ATN), where tubular damage and
altered glomerular hemodynamics may coexist or even lead
to each other [1–3]. In some cases of either human ARF [4,
5] or experimental models of renal injury [6], a lack of
correlation between histological evidence of injury and
renal function has been found, and the relative contribution
offunctional versus structural changes to the evolving renal
dysfunction has not been unequivocally substantiated.
Since ATN is a dynamic clinical condition, rapidly evolv-
ing from the incipient to the established phase, its early
identification is critical. However, the various currently
available methods of clinical and laboratory assessment are
insufficient to differentiate between ischemic ARF, result-
ing in acute tubular dysfunction secondary to cell injury,
and prerenal azotemia, characterized by decreased glo-
merular filtration but no epithelial cell injury. The inability
to distinguish between these situations leads to long dis-
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evolving renal failure. Renal biopsy provides limited data
because of the small sample size and the very focal pattern
of tubular injury [2, 7]. In addition and most importantly, it
is impractical in the human syndrome. Functional data in
early phases are also of little help, because prerenal
azotemia becomes an important consideration at that time,
and only the evolution of the clinical situation really
defines the nature of the problem [8, 9]. The utilization of
specific urinary biomarkers of tubular injury, such as KIM-
1, is not yet considered valid or sufficiently sensitive to
establish ATN [10, 11]. Moreover, these tests remain
qualitative rather than quantitative markers of injury. Since
therapeutic interventions might differ at various points in
the evolution of ATN, advanced techniques are required to
noninvasively follow the dynamic status of tubular injury.
Furthermore, a technology that enables imaging endpoints,
instead of time-consuming dissection and detection of renal
parenchymal cellular damage, would be highly valuable.
Multiple lines of evidence suggest that both apoptotic
and necrotic cell death are important pathogenic mecha-
nisms in acute renal failure [12, 13], where renal paren-
chymal cells are the primary target of a broad spectrum of
inciting factors, ranging from ischemic and nephrotoxic
agents to endotoxemia. Apoptotic cell death is a feature of
both ischemia–reflow injury [14] and radiocontrast-in-
duced acute renal failure [15], and is a documented event in
transplant biopsy as well [16]. The role of apoptosis in
sepsis syndrome has not been adequately explored, but
there is rapidly developing evidence to suggest that
increased apoptotic processes may play a determining
role in the outcome of sepsis syndrome [17, 18]. Although
apoptosis is recognized as playing a role in these
conditions, there is a lack of sensitive markers to monitor
programmed cell death in association with disease pro-
gression or regression.
Recently, we developed a family of small molecule
compounds, ApoSense, capable of discriminating between
vital and apoptotic cells. ApoSense molecules are small
non-peptidic fluorescent compounds that are capable of
selective targeting, binding, uptake, and accumulation
within apoptotic and/or necrotic cell cytoplasm, from the
early stages of the death process. Our preliminary results
from different animal models associated with apoptosis
showed that the recognition of damaged cells by ApoSense
is universal, irrespective of the cell type or the apoptotic/
necrotic trigger. Indeed, examined in multiple animal
models, ApoSense was proven to be a highly sensitive and
specific sensor for in vivo detection of neoplastic, hepatic,
myocardial, atherosclerotic, and neuronal apoptotic and
necrotic cell death (in preparation). In the present study the
potential of both fluorescent and radiolabeled derivatives
of one of the ApoSense compounds, didansyl cystine
(DDC), was explored as a diagnostic imaging agent for
detection of renal tubular injury in three different in vivo
animal models of ATN: renal warm ischemia/reperfusion,
radiocontrast-induced distal tubular necrosis, and cecal
ligature/perforation-induced sepsis. These different models
illustrate the applicability of ApoSense as a diagnostic
imaging agent enabling real-time accurate detection of
renal parenchymal damage of various types, and evaluation
of its distribution and magnitude.
Materials and methods
Male Sprague-Dawley rats weighing 180–250 g and 8- to 10-week-
old C57Bl mice (Harlan Laboratories, Jerusalem, Israel) were used
for these experiments. All experimental protocols were performed
according to the Guiding Principles for Research Involving Animals,
and approved by the local Animal Care Committee; the experiments
described in this manuscript also comply with the current laws of
Israel.
ApoSense synthesis and radiolabeling
The ApoSense compound used in the present study was N,N′-
didansyl-L-cystine (DDC). Both its inherent fluorescent character-
istics and its radiolabeled derivative (labeled with
3H radionuclide)
were used for identification and quantification of apoptotic cells.
For DDC synthesis, dansyl chloride (675 mg) and cystine
(240 mg) were dissolved in water/acetone solution with potassium
carbonate (550 mg), and after 1.5 h at room temperature, the aqueous
mixture was extracted with ethyl acetate. The crude DDC was
dissolved in 5% sodium carbonate, washed with ether, and reacid-
ified to pH 3 to afford a yellow precipitate. The product was analyzed
using
1H-NMR.
Labeling of DDC with
3H was performed by consecutive addition
of 0.16 mg cystine (0.65 μmol), 0.57 mg sodium carbonate
(5.3 μmol), and 37 MBq (1 mCi) of
3H-dansyl chloride (Vitrax) at
a concentration of 1.4×10
−4 mmol. The product was purified using a
Bond-Elut C-18 cartridge eluted with 25% acetonitrile in 0.1% TFA
in water, then lyophilized and dissolved in 1 ml of NaPPi buffer
(0.1 M, pH=7.4). Radiochemical purity was assessed by thin-layer
chromatography.
Evaluation of ApoSense binding to apoptotic cells in vitro
Human adult T-cell leukemia Jurkat cells (clone E6-1) and cervical
carcinoma HeLa cells (CCL-2.2), were purchased from ATCC
(Rockville, MD, USA) and grown in Dulbecco’s modified Eagle’s
medium with 10% fetal calf serum at 37°C in 5% CO2. For induction
of apoptosis in the Jurkat cell sample, 1×10
6 cells/ml were treated
with IgM anti-Fas (CD95) antibody, clone CH11 (Medical and
Biological laboratories, Japan) at a concentration of 0.1 μg/ml for
120–180 min. In additional studies, before incubation with anti-Fas
antibody, Jurkat cells were subjected to 50 μM of caspase inhibitor Z-
VAD-FMK in 0.05% DMSO (Enzyme System Products, Dublin,
CA). For apoptosis induction in HeLa cells, growing cells were
treated with staurosporin (STS; 250 nM; Sigma) for 18 h. At the end
of the incubation period, cells were harvested by trypsinization
(Trypsin-EDTA, Bet-Haemek,Israel) and collected by centrifugation.
For assessment of apoptosis, both fluorescence microscopy and
flow cytometry were employed. Trypsinized HeLa cells were
incubated with DDC (50 μM) and annexin V-FITC (Phosphatidyl
Serine Detection Kit, IQP-116F) for 20 min and the staining pattern
was evaluated under a fluorescence microscope (BX51TF; Olympus
Optical.Co., Ltd., UK) equipped with relevant filters. For DDC
staining, excitation at 365 and emission at 420 (band pass) nm was
employed, whereas for FITC detection, excitation was at 488 nm and
emission at 530 nm. Apoptotic Jurkat cells were detected by flow
cytometry after double staining with annexin V-FITC and PI or with
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6 cells/ml) was
diluted in 300 μl Hepes buffer (10 mM Hepes and 140 mM NaCl,
pH 7.4) containing annexin V-FITC/PI or 50 μM of DDC/PI. Fol-
lowing 40 min of incubation at room temperature, the cells were
subjected to analysis using FACS Vantage VE (BD Biosciences, San
Jose, CA) and CellQuest software. A total of 10,000 events were
collected for each sample.
Evaluation of ApoSense uptake into apoptotic/necrotic cells in vivo
The detection of renal parenchymal cell death by ApoSense was
assessed in three animal models of ATN, generally classified under
ischemic and septic etiologies [19–21].
Rat renal ischemia–reperfusion (I/R) model Operative pro-
cedures were performed in rats under general anesthesia induced by
the combination of ketamine, 80 mg/kg, and xylazine, 10 mg/kg,
Fig. 1. Concomitant confocal imaging of HeLa cell undergoing
apoptosis by DDC (green fluorescence) and annexin V (red fluo-
rescence). DDC accumulates within the cytoplasm of the apoptotic
cell while annexin V is attached to the external membrane
Fig. 2. Binding of DDC to apoptotic cells is caspase dependent.
Jurkat cells were treated with CD95 in the absence (red line)o r
presence (black line) of the pan caspase inhibitor z-VAD-fmk for
150 min. Following incubation, cells were centrifuged and
incubated in the presence of DDC for 40 min before FACS analysis.
This histogram charts the number of cells counted (y-axis) and the
fluorescence intensity (x-axis). The green line represents the control
non-apoptotic sample
Fig. 3. DDC uptake into renal damaged areas. a,b Ex vivo images of
the left ischemic (a) and the right sham-operated (b) kidney derived
from a single I/R rat (×7). Whole organs were viewed under a
stereomicroscope using a NU filter set without light flux, 4 h after
DDC administration. c,d Histological sections of kidneys (c, ×100;
d, ×600) revealing intense uptake along the tubule epithelium or in
the tubule lumen. e A quantitative estimate of DDC uptake into I/R
ischemic and intact (sham) kidney from five rats, normalized to total
injection dose for each gram of tissue. Values are means±s.e.m.
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lateral left renal artery clamping, using a small nontraumatic vascular
clamp, for 45 min [12]. Reperfusion was initiated by removal of the
clamp. The period of renal reperfusion was 24 h. Preliminary experi-
ments revealed no difference between the I/R rat contralateral kidney
and sham-operated normal rat kidneys with regard to cell death of
renal tubular epithelium after 24 h. Thus, in the present study, the
contralateral, untreated kidney from the same animal served as the
sham-operated control kidney. During the course of reperfusion,
animals were injected intravenously with 20 mg/kg of DDC and 4 h
later both kidneys were excised, frozen in liquid nitrogen, and stored
at −70°C until use. For microscopic analysis and fluorescence imag-
ing, 5-μm-thick cryo-sections of both kidneys were evaluated either
by fluorescence microscopy or were stained with hematoxylin and
eosin (H&E) for light microscopy analysis of apoptotic and/or ne-
crotic lesion distribution. Furthermore, the presence of apoptotic cell
nuclei was confirmed by apoptosis detection kit staining (ApopTag
FluoresceinKit,IntergenCompany,Purchase,NY)usingtheTUNEL
(terminal deoxynucleotidyltransferase-mediated uridinetriphosphate
nick end labeling) method. Additional ex vivo whole organ fluores-
cence imaging was carried out on freshly excised kidneys analyzed
under a Leica (Leica MZ FL III, Leica, Switzerland) stereomicro-
scope. DDC was visualized using a 360Ex and >420Em nm (NU) filter
set. Emitted fluorescence was collected on a Leica DC 300F digital
camera and images were processed and analyzed by Leica QWin Lite
software. For quantitative analysis of the extent of renal DDC accu-
mulation, previously frozen kidneys were thawed, weighed, and
homogenized in buffer containing 50 mM Tris-HCl and 0.005%
Triton X-100, pH 7.4 (1:7 w/v), using Heidolph RZR 2020
homogenizer (Heidolph Instruments GmbH & Co. KG, Schwabach,
Germany). Solubilized tissue extract samples were centrifuged twice
at 13,800 rpm (20 min, 4°C) and the supernatant fractions were
analyzed using a microplate reader (GENious Fl Reader, TECAN,
Fig. 4. Morphological evidence
for renal tubular cell apoptosis/
necrosis following ischemia–re-
flow. a Tubular cells (H&E
staining) are seen with changes
typical of apoptosis (left). In an
adjacent 5-μm section (right),
these cells take up DDC. ×1,000.
b Necrotic tubular cells in tu-
bular lumina (H&E staining;
left) and corresponding DDC
fluorescence of the same injured
cells (right). ×400. c Co-local-
ization of DCC fluorescence
(right) with TUNEL-positive
nuclear staining (left). Some
cells are likely in the early
stages of apoptosis and are
TUNEL negative, but take up
DDC (arrow). ×200
Fig. 5. Biodistribution of radiolabeled
3H-DDC after renal I/R
treatment. Uptake of
3H-DDC (% injected dose per gram corrected
for background) in target and non-target tissues, determined 18–24 h
after ischemia and 4 h after
3H-DDC administration, is shown. Data
are presented as mean±s.e.m., n=7. Asterisks denote significantly
higher accumulation of
3H-DDC in ischemic kidney compared with
other organs (tissues): *p<0.05, **p<0.01
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surements. All samples were pipetted in triplicate onto black Ritter
flat bottom microplates and read at 360 nm Ex and 535 nm Em. For
the calibration curve, a dilution series of DDC were prepared in the
same Tris-Triton buffer, supplemented with 0.05% kidney extract of
control vehicle-injected animals. The same control animal samples
were also used for background values. In all samples, DDC concen-
tration (μg/g tissue) and the percentage of the injected dose (% ID/g)
were calculated.
Additional biodistribution studies were carried out to assess the
spread of radiolabeled DDC into different organs. Twenty-four hours
after unilateral renal ischemia/reperfusion, rats were intravenously
injected with 5–20 μg/kg of the tritiated form of DDC (
3H-DDC)
[111–370 kBq (3–10 μCi)/animal]. Four hours later, both kidneys,
liver, gut, and blood samples were collected, weighed, and submitted
to lyses by SOLVABLE reagent (GNE9100, Packard Bioscience),
accordingtothemanufacturer’sinstructions,andsampleradioactivity
was determined using a beta counter (TRI-CARB 2100TR, liquid
scintillation analyzer,PackardBioscience). Both tissue uptake(%ID/
g) and the ratios of the radioactivity of the ischemic kidney (DPM/g)
tothatofthecontralateralkidneyandtheothernon-targettissueswere
calculated.
Rat model of radiocontrast-induced distal tubular necrosis
(DTN) The selectivity of DDC uptake in injured renal tissues was
evaluated in this rat model, characterized by selective medullary
hypoxic tubular damage. Nephropathy was induced by the combined
administrationofindomethacin(SigmaChemicalCo.),10mg/kg,i.v.,
N-ω-nitro-L-arginine methyl ester (L-NAME, Sigma Chemical Co.),
10 mg/kg, i.v., and the radiocontrast agent sodium iothalamate 80%
(Angio-Conray, Mallinckrodt Inc), 6 ml/kg, i.a., as previously de-
scribed [22]. The study was performed on six rats, with an additional
two rats injected with vehicles serving as control (these two control
animals studied are representative of at least 29 control rats tested in
our previous experiments). Twenty-four hours after insult, animals
were intravenously injected with 20 mg/kg DDC and 2 h later they
were sacrificed. The left kidney was removed and snap-frozen for
fluorescence analysis (and for H&E and TUNEL staining, as detailed
above), whereas the right kidney, used for morphological evaluation,
was in vivo fixed with glutaraldehyde perfusion through the abdom-
inal aorta, as described elsewhere [22, 23]. Perfusion-fixed kidneys
were immersed in buffered 2% OsO4, dehydrated, and embedded in
an Araldite-EM bed 812 mixture. Large sections were cut perpen-
dicular to the renal capsule, containing cortex and medulla, including
fornix and papillae. One-micrometer sections were stained with
methylene blue and analyzed in a blinded fashion (i.e., without
knowing the fluorescence results) for morphological alterations. As
previously detailed [23], tubular necrosis was determined separately
for S3 proximal tubules in the outer stripe and medullary rays,and for
medullarythickascendinglimbs(mTALs)intheouter,mid,andinner
zones of the inner stripe of the outer medulla. The extent of damage
was expressed as the percentage of necrotic tubules out of total
tubules counted. Papillary necrosis was semiquantitatively assessed
using a score of 0–3.
Sepsis model in the mouse The sensitivity of cell death recog-
nition by DDC was tested in the cecal ligature and perforation (CLP)
model in mice, where rare, focal tubular cell damage is hardly
detected by regular morphological evaluation [24, 25]. The cecum of
six anesthetized mice was isolated, ligated distal to the ileocecal
valve, and punctured twice with a 26-gauge needle. An additional
four sham-treated animals were laparotomized, but the cecum was
Fig. 6. Renal macroscopic and microscopic findings in rats subjected
to the ARF protocol (indomethacin, L-NAME and iothalamate) and
subsequently injected with DDC. a Macroscopic view of the
characteristic striped pattern of severe hypoxic outer medullary
damage in an in vivo fixed kidney. b The in vivo microscopic
distributionofDDCinthecontralateralkidneycorrelatescloselywith
thedistributionofthestripedpatternofoutermedullarynecrosisinthe
ipsilateral one (×30). c Details (×100) of the cross-section, showing
fluorescent imaging of DDC uptake in injured areas of both the inner
strip and the forniceal region of the outer medulla. Examination of
contiguous 5-μm sections revealed that the accumulation of DDC in
damaged areas (d, upper panel) matched the infarct areas stained by
TUNEL (d, lower panel) (×200). OM outer medulla,IM inner
medulla, SP secondary pyramid
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injectedi.v.withDDC,and2hafterwards,kidneyswereremovedand
subjected to fluorescence microscopy analysis as detailed above.
Statistical analysis
Data reported are mean±s.e.m. Student’s t test was used to assess the
significance of differences between two groups. Significance was
accepted at p<0.05
Results
Binding of ApoSense to apoptotic cells in vitro
Concomitant confocal imaging of HeLa cells undergoing
apoptosis, double stained with DDC and annexin V,
revealed that DDC accumulates within the cytoplasm of
the apoptotic cell while annexin V is attached to the
external apoptotic cell membrane (Fig. 1). Accumulation of
ApoSense within apoptotic cells can contribute to ampli-
fication of the signal obtained and consequently to the high
signal-to-noise ratio. Previous studies have shown that
through an interaction with the death receptor CD95
induces apoptosis by formation of a signaling complex at
the cell membrane and subsequent caspase-8 and caspase-3
activation [26]. Therefore, the specificity of DDC uptake
was tested in apoptotic Jurkat cells that were co-treated
with caspase inhibitor and analyzed by flow cytometry. As
shown in Fig. 2, in viable, non-apoptotic cells (green line),
no uptake of DDC was detected, except in a small
population of spontaneously dying cells representing late
events. Following 150 min of incubation with anti-Fas,
most cells accumulated DDC and created a new peak of
cells (red line) with a higher fluorescence intensity (the
geometric mean fluorescence intensity value, GMFI, was
120.18) while the peak of late apoptotic cells remained
unchanged. In the presence of the caspase inhibitor Z-
VAD-FMK, cells lost the ability to bind DDC (black line),
while their viability remained preserved, suggesting that
accumulation of DDC compound is dependent on the
apoptotic process itself. Upon addition of the caspase
inhibitor, a marked shift towards a lower fluorescence
Fig. 7. Characteristic morpho-
logical findings in rats subjected
to the ARF protocol and injected
with DDC. Cryo-sections from
the left kidney were used for
DDC fluorescence analysis,
whereas the in vivo fixed right
kidney was used for light mi-
croscopy morphological exami-
nation of methylene blue-stained
slides. Analyses of both kidneys
were performed in a blinded
fashion. An example is shown
of the striped pattern reflecting
the damage gradient, where tu-
bules adjacent to the vasa recta
(VR) are preserved (red stars)
while those distant from vasa
recta are injured (black stars)
(a, left panel, ×100). Note the
excellent co-localization of
morphologically damaged tu-
bules with the DDC fluores-
cence (a, right panel, ×100) in
the contralateral kidney. DDC
fluorescence was selectively
identified in all morphologically
injured regions, including pa-
pillary tip structures (b: left
panel ×40, right panel ×100)
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almost the same as the control cell values (GMFI 46.38 and
46.02, respectively), suggesting maximal inhibition.
ApoSense uptake into ischemia/reperfusion (I/R) injured
kidneys
Evaluation of DDC accumulation into injured tubular cells
of an ischemic rat kidney was performed on the basis of its
intrinsic fluorescent properties. Either ex vivo whole
kidney fluorescent imaging or cryo-section fluorescent
analysis was employed. As seen in Fig. 3, DDC accu-
mulated in the injured (a) but not in the contralateral intact
kidney (b), thereby exhibiting substantial capability for
imaging apoptosis and/or necrosis in vivo. Microscopic
analysis of corresponding kidney sections revealed intense
cytoplasmatic staining of tubular epithelial cells (Fig. 3c,d)
located at the corticomedullary junction. No uptake of
DDC into viable renal parenchyma was detected. The
extent of DDC accumulation in these cells was quantita-
tively determined in homogenized whole kidney extracts
from five rats, using microplate reader fluorescence mea-
surement. As shown in Fig. 3e, the average DDC uptake
into the ischemic kidney (expressed as %ID/g) was 6.73±
1.34 fold higher (p=0.0076) than that in the intact control
kidney (0.41±0.11 and 0.06±0.02, respectively). H&E-
stained histological sections of kidneys from I/R-treated
rats revealed multiple apoptotic as well as necrotic cells
situated along the tubule epithelium or in the tubule lumen
(Fig. 4). A spectrum of changes characteristic of tubular
cell apoptosis, including shrinkage of renal tubular cells,
cytoplasmic acidophilia, chromatin dense condensation
and margination, nuclear fragmentation, and pyknosis, is
shown in Fig. 4a, left. In addition, as previously described
[27–30], a large percentage of tubules in this region
showed substantial tubular dilatation, epithelial necrosis,
dissolving of tubular cells, luminal necrotic debris, and cast
formation (Fig. 4b, left). The presence of apoptotic/necrotic
cells was also defined by intensive green fluorescence of
TUNEL-positive nuclei (Fig. 4c, left). As shown in
Fig. 4a–c, right panel, the accumulation of DDC within
the damaged areas in ischemic kidneys corresponds com-
pletely, even at the single cell level, to the injured areas
detected by H&E and TUNEL staining. However, it seems
that in some areas, accumulation of DDC in apoptotic cell
cytoplasm occurred earlier than DNA destruction and
thereby cells were not stained by TUNEL but merely by
DDC (Fig. 4c, arrow). These results may indicate that
DDC has the ability to identify early apoptotic cells and
that use of TUNEL alone may not reveal the full spectrum
of cell death stages.
Biodistribution studies of
3H-DDC were performed in
seven additional rats following the I/R procedure. The
accumulation of radioactivity in the blood, gut, liver and
kidney at 4 h after intravenous administration is shown in
Fig. 8. Focal uptake of DDC in
kidneys of six mice following
sepsis caused by cecal ligature
and perforation (CLP). Apopto-
tic cells, imaged by DDC, were
shown either in the outer me-
dulla (a, left) or in the cortex
(a, right) of individual mice
(×100). Most apoptotic cells
appeared to be tubular epithelial
cells (b, left, arrows). An evi-
dent correlation was demonstra-
ted between DDC fluorescence
(b, right and c, right) and
apoptotic cells detected on H&E
(b, left) or TUNEL (c, left)
stained slides (×200)
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higher than that in the intact contralateral one(p<0.05) and
also higher than liver, gut and blood uptake values
(p<0.01). The average uptake values at 4 h, rendered as
% ID/g, were 1.20±0.13 for the ischemic kidney, 0.58±0.12
for the intact kidney, 0.41±0.07 for the liver , 0.42±0.09
for the gut, and 0.28±0.01 for blood. The corresponding
mean ischemic kidney-to-tissue ratios were 2.1±0.5, 2.9±
0.5, 2.8±0.7, and 4.3±0.6, respectively. These results in-
dicate that at 4 h following administration, DDC remained
accumulated in the target organ, while being cleared from
non-target ones.
Radiocontrast-induced distal tubular necrosis
Heyman et al. [23] reported previously that animals
subjected to the radiocontrast model of DTN developed
varying degrees of renal dysfunction and structural
damage, but the presence, distribution, and extent of
tubular injury on an individual basis could not be predicted
from the magnitude of kidney dysfunction. In the present
study, as well as in previously published studies [22, 23,
31], renal morphology analysis disclosed a wide-ranging
extent of medullary (namely mTALs and S3 segments in
the outer medulla and medullary rays) and papillary
damage, with a poor overall correlation between structural
damage and functional deterioration (data not shown). By
contrast, as shown in Figs. 6 and 7, DDC distribution
pattern and degree of deposition closely mirrored the
morphological findings in the contralateral perfused kid-
ney, suggesting that ApoSense uptake may reflect the level
anddegree of renal damagemore closely than dofunctional
tests. Results from both fluorescence and morphological
analysis disclosed the characteristic striped pattern of
injury (Fig. 6a,b), where tubules adjacent to the vasa recta
are preserved while those distant from vascular bundles are
injured (Fig. 7a). Homing of DDC was primarily restricted
to injured regions within the outer medulla (Fig. 6c). No
DDC uptake at a specified region in the absence of
morphological damage was seen, as demonstrated in
Fig. 7b, where necrosis of the papillary tip in one of the
kidneys was clearly morphologically demarcated and DDC
deposition was restricted to precisely the same injured area.
Uptake occurred preferentially in apoptotic/necrotic le-
sions, as confirmed by co-localization with TUNEL
staining (Fig. 6d). Thus, DDC was found to be a specific
molecular marker for tubular injury in various segments of
the kidney.
Cecal ligature/perforation-induced sepsis
DDC was evaluated as a potential in vivo marker for renal
tubular cell apoptosis in another animal model of ATN, in
which sepsis-associated renal dysfunction was induced by
cecal ligation and puncture. Morphological alterations of
the kidney due to sepsis can hardly be identified using
routine histological techniques [32, 33], and experimental
data regarding the apoptotic cells of kidneys affected by
sepsis are therefore almost non-existent. Indeed, in all
septic mice we found only rare focal renal tubular cell
injury, seen either in the outer medulla or in the cortex
(Fig. 8a). As seen in Fig. 8b, focal renal tubular cell injury
is apparently identified by DDC fluorescence, but is not
clearly traced using H&E histopathological analysis; this
demonstrates the high sensitivity of DDC in the detection
of such renal damage. TUNEL staining confirmed the
presumption that renal cells stained by DDC are indeed
dying cells (Fig. 8c).
Discussion
As a result of recent progress in medicine, biology, and
physics, the field of diagnostic imaging is shifting from
conventional anatomical imaging to the sphere of func-
tional and molecular imaging, with the aim of imaging
biological processes related to both health and disease. The
implementation of the new ApoSense technology for
clinical imaging of apoptosis would represent a major
addition to this emerging field, allowing non-invasive
imaging of cell death processes in vivo as a means to both
the diagnosis of disease and the monitoring of treatment
efficacy in a broad spectrum of disease states.
In the present study, we have reported the successful
application of ApoSense technology as a diagnostic
imaging tool for the detection of apoptotic and/or necrotic
cell death. ApoSense technology may be particularly useful
in ARF, where current clinical and physiological assess-
ment and complementary imaging tests are insufficient to
discriminate between true renal parenchymal damage and
prerenal azotemia (in which kidney filtration function is
drastically reduced even though the internal structures of
the kidney are intact). An inherent fluorescent property of
one of the ApoSense family of compounds, DDC, was
utilized for detection of tubular cell death in three animal
models of ATN. The results obtained are in complete
agreement with in vitro findings of DDC-specific binding
to apoptotic cells (Figs. 1, 2), and thereby strongly suggest
the ability of DDC to image renal tubular cell apoptosis in
vivo.
The three in vivo experimental models of ATN used in
the present study complement each other regarding the
applicability of ApoSense technology in the detection of
ATN. The results obtained using the I/R model showed the
qualitatively remarkable capability of ApoSense in target-
ing of injured tissues and ex vivo imaging of apoptosis
(Fig. 3). Additionally, the model provides quantitative
analysis of the extent of renal tubular cell damage based on
the extent of DDC accumulation in these cells. It was
shown that the uptake of DDC in the ischemic kidney was
6.73-fold higher than in the non-ischemic one. Moreover,
the specificity of targeting of the injury by ApoSense was
demonstrated by its localization to regions of apoptotic/
necrotic cell death, detected by H&E and TUNEL staining
(Fig. 4). Furthermore, it was observed that some TUNEL-
negative cells with a normal overall nuclear morphology
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ceivably representing cells in the initial phases of
apoptosis. These results possibly indicate that ApoSense
technology can provide a tool which will directly assess for
early stages of programmed cell death in the ischemic
kidney, before membrane vesicle formation and DNA
degradation, particularly as measured by the TUNEL
method [34].
The radiocontrast model of distal tubular necrosis
provides a good example of specific targeting by ApoSense.
Indeed, the presence of DDC was restricted to regions
(medullary outer and inner stripe; papillary tip) that cor-
responded closely to the injured zones in the contralateral,
perfusion-fixed kidney (Figs. 6, 7). Methylene blue-stained
thin sections from those in vivo fixed kidneys enabled
precise evaluation of the renal morphology and accurate
identification of tubular cell types at various stages of
evolving structural damage. The complete correlation
between DDC fluorescence and histological evidence of
damaged areas, mainly made up of apoptotic and necrotic
cells, is indicative of the specificity of DDC uptake. Thus,
while the degree of renal dysfunction served as an in-
accurate indicator of tubular injury [4, 5], ApoSense uptake
closely predicted the existence of ATN, with an absolute
specificity for involved tubular segments.
Our findings derived from the mouse sepsis model
further illustrated the sensitivity of ApoSense in the
detection of rare focal tubular cell injury that is not well
defined by routine H&E staining (Fig. 8). It has to be
reiterated that data regarding the morphology of sepsis-
related ATN are nearly non-existent, mainly because such
rare, focal tubular cell damage can hardly be detected by
regular morphological evaluation [35, 36].
The inherent fluorescent properties of the ApoSense
molecule DDC have been used in the present study to
evaluate its specific binding to apoptotic cells. On the other
hand, the structure of ApoSense molecules is modular,
allowing for versatile attachment of various clinical
imaging markers and, therefore, enabling their use as
non-invasive imaging agents. In the current study, a
3H-
labeled DDC molecule was used for biodistribution and
quantitative uptake studies. Nevertheless, autoradiography
with radiolabeled DDC was not performed in this series of
experiments and this may be the main limitation of the
present study. Moreover, additional studies based on
preparation of ApoSense as a PET imaging agent (follow-
ing its conjugation with
18F) are necessary before the
introduction of the technology in the form of diagnostic
imaging tests. These studies are currently in progress.
Overall, the results presented here are promising and
illustrate the high sensitivity and specificity of ApoSense in
the assessment of tubular cell damage in multiple ex-
perimental templates that may have clinically relevant
applications. For instance, ApoSense technology may be
implemented for the in vivo assessment of the degree to
which renal parenchymal cell apoptosis is contributing to
renal failure in sepsis and for the differentiation of evolving
ATN from renal hemodynamic alterations; as a result it can
enable therapy to be tailored to each patient’s needs. The
ability of radiolabeled derivatives of ApoSense to visualize
both apoptosis and necrosis, non-invasively and in real-
time, may prove useful in reducing the need for routine
biopsy. Furthermore, in clinical practice, ApoSense imag-
ing may provide diagnostic information superior to that
obtained by means of biopsy, especially as regards the
dynamic nature and focal distribution of the disorder;
furthermore, it does not suffer from the risks and
limitations associated with tissue sampling.
Imaging sciences have grown tremendously during
recent decades, and many non-invasive techniques for the
detection and monitoring of renal hemodynamics, such as
advanced ultrasonography techniques, magnetic resonance
imaging, and nuclear and X-ray computed tomography
[37–39], have become essential clinical tools. Similarly,
non-invasive technologies and imaging probes that would
enable the detection of evolving renal parenchymal
apoptotic and necrotic injury are critically needed. During
the past few years, the best-characterized apoptosis marker,
annexin V, a calcium-dependent phospholipid binding
protein [40, 41], has been extensively investigated in
multiple animal models as well as in clinical trials [42].
However, annexin V has a strong affinity for intact renal
cortex, which has been attributed to the intrinsic lipid
profile of the kidney, where a high concentration of
phosphatidylserine exists [43, 44]. The high accumulation
of annexin V in the kidneys precludes its use for the study
of apoptosis in these organs or in their immediate vicinity
[45, 46]. In addition, the biological rationale for engineer-
ing DDC, a small non-peptide molecule with a molecular
weight of 700 Da (as compared with the 36-kDa annexin V
protein), is that such small molecules could benefit from
less immunogenicity and the favorable biodistribution
kinetics that small compounds in general exhibit over
bigger proteins.
In summary, this study demonstrates that ApoSense,
once successfully radiolabeled with an imaging moiety,
may provide a sensitive means for real-time diagnosis and/
or monitoring of the extent of renal damage in ATN,
utilizing selective targeting, binding, uptake, and accumu-
lation within renal tubular apoptotic and/or necrotic cells.
Moreover, as a non-invasive method, ApoSense imaging
would allow longitudinal studies in a single individual,
rendering important information on the optimal timing
and dosing of drugs and on the efficacy of therapeutic
interventions.
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